Skip to main content

Catheter Disinfection Caps Cut Infection Rates


Central line–associated bloodstream infections (CLABSIs) declined sharply during a study that tested alcohol-impregnated disinfection caps with catheters in place of the standard scrubbing protocol. The suburban Chicago hospitals involved in the study have since adopted the use of the cap as standard practice.
Marc-Oliver Wright, MT, MS, CIC, from the Department of Infection Control, NorthShore University Health Systems, Evanston, Illinois, and colleagues reported their results in anarticle published in the January issue of the American Journal of Infection Control.
The investigators conducted a 3-phase quasi-experimental study of adults with central lines installed at 3 hospitals in 2009: first with standard scrub protocol, second (intervention) with the cap used, and third with standard scrub used again. At a fourth hospital, they tested just the intervention because of limited resources. The plastic-threaded cap houses a sponge saturated with 70% isopropyl alcohol.
The researcher found that contamination of the lines declined from 12.7% (32/252 patients) during the first phase to 5.5% (20/364 patients; P = .002) during the intervention and rose back to 12.0% (22/183 patients; P = 0.88 vs phase 1 and P = .01 vs phase 2) in the third phase ( P = .001 vs intervention).
The researchers also found that the median colony-forming units per milliliter amounted to 4 for the first baseline period, 1 for the intervention ( P = .009), and 2 for the second baseline period ( P = .05 vs intervention).
CLABSI rates declined from 1.43 per 1000 line-days (16/11,154 days) in the first baseline to 0.69 (13/18,972 days) in the intervention ( P = .04) and rose back up to 1.31 (7/5354 days) in phase 3, when all 4 hospitals are included in the analysis (risk ratio, 0.48; 95% confidence interval, 0.23 - 0.98; P = .04).
As a control measure, the researchers calculated catheter-associated urinary tract infection rates, which were stable during the first 2 phases (1.42 and 1.41, respectively; P = .90) but declined in the third phase (1.04; P = .03 vs the first 2 phases).
"Not surprisingly, among the patients with intraluminal contamination the most commonly recovered organism was coagulase-negative Staphylococcus species (18/32, 12/20, P = 1.00), a skin colonizer and frequent cause of CLABSI," the researchers write.
Cost Analysis
The researchers also conducted an economic analysis, calculating the total cost of the disinfection cap at $60,233 per year and using the above risk ratio to propose a 52% reduction in infections for all 4 hospitals. "For a cost of $2.07 per catheterized patient per day, we avoid 21 infections and 4 deaths and make enough beds available for 13 new admissions," the researchers write.
"Preventing catheter hub contamination can take many forms," the researchers write. "The approach of using a continuously applied alcohol impregnated sponge as a cap on the hub for a standard approach to catheter care may eliminate the problem of teaching health care providers one additional disinfection process they need to use as part of their busy patient care schedule."
Limitations of the study include the use of surveillance-based CLABSI results that may overestimate clinical disease occurrence, as well as the inclusion of results from the fourth hospital that conducted the intervention phase only, the researchers write.
In fact, when the investigators do not include the intervention-only site, the difference in CLABSI rates per 1000 central line days lacks significance in the remaining 3 hospitals ( P = .11), despite a 49% decline compared with baseline rates.
"We think it is reasonable to include the data from this hospital because it is part of our health care organization and practices there are the same as at our other 3 facilities. The only reason it was not part of the formal investigation was that we did not have sufficient resources to collect samples at that site, and so we implemented the disinfection cap as a standard practice at the onset. Measurement of CLABSI was identical at this hospital as it was for the other 3 in the formal study." they explain.
The researchers conclude, "At the conclusion of this investigation, our Infection Control Committee approved the permanent introduction of this device for use with central lines, and it is now the standard of practice for the organization."
The authors have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...